Literature DB >> 26457027

Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.

I-Ting Wu1, Seng-Kee Chuah1, Chen-Hsiang Lee1, Chih-Ming Liang1, Lung-Sheng Lu1, Yuan-Hung Kuo1, Yi-Hao Yen1, Ming-Luen Hu1, Yeh-Pin Chou1, Shih-Cheng Yang1, Chung-Mou Kuo1, Chung-Huang Kuo1, Chun-Chih Chien1, Yu-Shao Chiang1, Shue-Shian Chiou1, Tsung-Hui Hu1, Wei-Chen Tai1.   

Abstract

AIM: To determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy.
METHODS: We analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively.
RESULTS: A high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend.
CONCLUSION: Antibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.

Entities:  

Keywords:  Antibiotic resistance; Failed first-line therapy; Five-year sequential changes; Helicobacter pylori; Southern Taiwan

Mesh:

Substances:

Year:  2015        PMID: 26457027      PMCID: PMC4588089          DOI: 10.3748/wjg.v21.i37.10669

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

2.  A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.

Authors:  Ping-I Hsu; Kwok-Hung Lai; Chiun-Ku Lin; Wen-Chi Chen; Hsien-Chung Yu; Jin-Shiung Cheng; Feng-Woei Tsay; Chung-Jen Wu; Ching-Chu Lo; Hui-Hwa Tseng; Yoshio Yamaoka; Jin-Liang Chen; Gin-Ho Lo
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

3.  High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia.

Authors:  Khean-Lee Goh; Parasakthi Navaratnam
Journal:  Helicobacter       Date:  2011-06       Impact factor: 5.753

4.  Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori.

Authors:  Monique M Gerrits; Egbert-Jan van der Wouden; Dorine A Bax; Anton A van Zwet; Arnoud Hm van Vliet; Albertine de Jong; Johannes G Kusters; Jaap C Thijs; Ernst J Kuipers
Journal:  J Med Microbiol       Date:  2004-11       Impact factor: 2.472

5.  Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazole.

Authors:  Hitoshi Tsugawa; Hidekazu Suzuki; Kazue Satoh; Kenro Hirata; Juntaro Matsuzaki; Yoshimasa Saito; Makoto Suematsu; Toshifumi Hibi
Journal:  Antioxid Redox Signal       Date:  2010-08-26       Impact factor: 8.401

6.  Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.

Authors:  Jung Won Lee; Nayoung Kim; Jung Mogg Kim; Ryoung Hee Nam; Hyun Chang; Jae Yeon Kim; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Helicobacter       Date:  2012-12-13       Impact factor: 5.753

7.  Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.

Authors:  E C Nista; M Candelli; F Cremonini; I A Cazzato; S Di Caro; M Gabrielli; L Santarelli; M A Zocco; V Ojetti; E Carloni; G Cammarota; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

Review 8.  Helicobacter pylori detection and antimicrobial susceptibility testing.

Authors:  Francis Mégraud; Philippe Lehours
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

Review 9.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

10.  In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations.

Authors:  M J Pavicić; F Namavar; T Verboom; A J van Winkelhoff; J De Graaff
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  9 in total

1.  Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori.

Authors:  Xiao-Feng Luo; Jian-Hua Jiao; Wen-Yue Zhang; Han-Ming Pu; Bao-Jin Qu; Bing-Ya Yang; Min Hou; Min-Jun Ji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

3.  Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.

Authors:  Lien-Chieh Lin; Tzu-Herng Hsu; Kuang-Wei Huang; Ka-Wai Tam
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

4.  A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.

Authors:  Seng-Kee Chuah; Chih-Ming Liang; Chen-Hsiang Lee; Shue-Shian Chiou; Yi-Chun Chiu; Ming-Luen Hu; Keng-Liang Wu; Lung-Sheng Lu; Yeh-Pin Chou; Kuo-Chin Chang; Chung-Huang Kuo; Chung-Mou Kuo; Tsung-Hui Hu; Wei-Chen Tai
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication.

Authors:  Hsiang Tso Huang; Hsin-Ming Wang; Shih-Cheng Yang; Wei-Chen Tai; Chih-Ming Liang; Keng-Liang Wu; Chen-Hsiang Lee; Seng-Kee Chuah
Journal:  Infect Drug Resist       Date:  2018-10-30       Impact factor: 4.003

6.  Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México.

Authors:  Margarita Camorlinga-Ponce; Alejandro Gómez-Delgado; Emmanuel Aguilar-Zamora; Roberto C Torres; Silvia Giono-Cerezo; Antonio Escobar-Ogaz; Javier Torres
Journal:  Front Cell Infect Microbiol       Date:  2021-02-11       Impact factor: 5.293

7.  Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan.

Authors:  Chih-Ming Liang; Wei-Chen Tai; Pin-I Hsu; Deng-Chyang Wu; Chao-Hung Kuo; Feng-Woey Tsay; Chia-Long Lee; Kuan-Yang Chen; Seng-Kee Chuah
Journal:  Therap Adv Gastroenterol       Date:  2020-12-10       Impact factor: 4.409

Review 8.  Second-line rescue treatment of Helicobacter pylori infection: Where are we now?

Authors:  Te-Fu Lin; Ping-I Hsu
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

9.  Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation.

Authors:  Ji Yeong Yang; Jong-Bae Kim; Pyeongjae Lee; Sa-Hyun Kim
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.